• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Re-use of mitomycin C in the treatment of superficial tumours of the urinary bladder: an evaluation in view of its chemical stability.

作者信息

Underberg W J, Beijnen J H

机构信息

Department of Pharmaceutical Analysis, Faculty of Pharmacy, State University of Utrecht, The Netherlands.

出版信息

Anticancer Res. 1987 Jul-Aug;7(4B):707-10.

PMID:3118758
Abstract

The possibility of re-using mitomycin C (MMC) containing solutions after intravesical instillation in the urinary bladder is evaluated in view of the chemical stability of the drug. Generalized positive conclusions about the re-use of these solutions are unjustified due to the possible variation in the urinary pH of individual patients. Only in cases where the urinary pH during treatment is greater than 6 may re-use be considered, provided that bacterial contamination can be avoided. In cases where the pH is too low (i.e. less than 6) a considerable degradation occurs during instillation (about 34% at pH 5) and storage during 1 week at 4 degrees C (about 25% at pH 5). On the other hand, considering the acid activation pathway, induction of a low urinary pH during treatment might enhance the efficiency, although re-use in this case is impossible.

摘要

相似文献

1
Re-use of mitomycin C in the treatment of superficial tumours of the urinary bladder: an evaluation in view of its chemical stability.
Anticancer Res. 1987 Jul-Aug;7(4B):707-10.
2
Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation.用于膀胱内灌注的溶液中抗肿瘤药物丝裂霉素C的化学稳定性。
J Parenter Sci Technol. 1990 Nov-Dec;44(6):332-5.
3
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.表浅膀胱癌患者膀胱内注射丝裂霉素C的药代动力学
Cancer Res. 1991 Oct 1;51(19):5144-52.
4
Re: Recurrence of superficial bladder carcinoma after intravesical instillation of Mitomycin-C.回复:丝裂霉素C膀胱内灌注后浅表性膀胱癌的复发
Br J Urol. 1989 Dec;64(6):659.
5
Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.浅表性膀胱癌中丝裂霉素C膀胱内化疗的治疗方案:短期疗程或维持治疗。
Urology. 1988 Mar;31(3 Suppl):26-9.
6
[Combination chemotherapy of mitomycin C and cytosine arabinoside in superficial bladder tumors. 1. Evaluation of intravesical infusion therapy].丝裂霉素C与阿糖胞苷联合化疗用于浅表性膀胱肿瘤。1. 膀胱内灌注治疗的评估
Gan To Kagaku Ryoho. 1983 Oct;10(10):2145-51.
7
[Intravesical chemotherapy for superficial bladder tumors].[浅表性膀胱肿瘤的膀胱内化疗]
Gan To Kagaku Ryoho. 1984 Aug;11(8):1557-62.
8
The stability and antitumor activity of recycled (intravesical) mitomycin C.回收(膀胱内灌注)丝裂霉素C的稳定性和抗肿瘤活性。
Cancer. 1984 May 15;53(10):2063-8. doi: 10.1002/1097-0142(19840515)53:10<2063::aid-cncr2820531010>3.0.co;2-5.
9
Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.EO9(阿帕喹酮)在人尿液中的稳定性实验:一种用于膀胱癌膀胱内治疗的新型抗癌药物。
J Pharm Biomed Anal. 2007 Jan 4;43(1):285-92. doi: 10.1016/j.jpba.2006.06.044. Epub 2006 Aug 22.
10
[Sequential intravesical chemotherapy with mitomycin C and adriamycin for superficial bladder tumor (preliminary report)].丝裂霉素C与阿霉素序贯膀胱内化疗治疗浅表性膀胱肿瘤(初步报告)
Hinyokika Kiyo. 1985 Apr;31(4):623-6.